Dr. Alvarez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
925 Gessner Rd
Ste 600
Houston, TX 77024Phone+1 713-827-9525Fax+1 713-468-3561
Summary
- Dr. Ricardo Alvarez is an oncologist in Houston, TX and is affiliated with multiple hospitals in the area, including Memorial Hermann Katy Hospital, Memorial Hermann Memorial City Medical Center, Memorial Hermann - Texas Medical Center, Memorial Hermann Southwest Hospital, Memorial Hermann Sugar Land Hospital, and Baylor St. Luke's Medical Center. He received his medical degree from Universidad Nacional de La Plata Faculty of Medicine and has been in practice 27 years. He specializes in breast cancer and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma. He has more than 70 publications and over 500 citings.
Education & Training
GSBS MD Anderson Cancer CenterMaster in Science, Tumor Biology, 2007 - 2010
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2004 - 2006
Texas Tech University HSC El PasoInternship, Internal Medicine, 2003 - 2004
Universidad Nacional de La Plata Faculty of MedicineClass of 1990
Certifications & Licensure
TX State Medical License 2007 - 2026
GA State Medical License 2014 - 2020- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase II Neoadjuvant in Inflammatory Breast Cancer Start of enrollment: 2008 Oct 01
- TKI258 for Metastatic Inflammatory Breast Cancer Patients Start of enrollment: 2012 Jan 27
- Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 Start of enrollment: 2012 Aug 03
Publications & Presentations
PubMed
- 77 citationsCirculating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination.Mario Giuliano, Antonio Giordano, S. Jackson, Ugo De Giorgi, Michal Mego
Breast Cancer Research. 2014-09-16 - 85 citationsThe role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.Ricardo H. Alvarez, Hagop M. Kantarjian, Jorge E. Cortes
Cancer. 2006-10-15 - 93 citationsLong-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypesHiroko Masuda, Takae Brewer, Diane Liu, Takayuki Iwamoto, Yu Shen
Annals of Oncology. 2014-02-01
Press Mentions
In Latest Findings from ASCO TAPUR Study Trial Presented at AACR Annual MeetingAugust 19th, 2019
Drug-Resistant TNBC: The Search for Novel Therapeutic ApproachesFebruary 20th, 2018
IBC: A Rare Form of Breast Cancer That You and Your Physician Should Know AboutOctober 17th, 2017- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
